Patent · US Expired

Vasomolol: an ultra short-acting and vasodilatory vanilloid type .beta..sub. - adrenoceptor antagonist

US5939578A · kind A · utility

2Cited by
1References
10Claims
0Family size

Assignee

Inventor

Key dates

Filing dateJun 21, 1996
Grant dateAug 17, 1999
Priority date
Expiry dateJun 21, 2016

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07C213/04
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

This invention is related to novel vasomolol, compounds of this invention have the following formula wherein R.sub.1 represents C.sub.1-4 alkyl group. ##STR1## vasomolol is an ultra short-acting and vasodilatory selective .beta..sub.1 -adrenoceptor antagonist, and is devoid of ISA. Vasomolol is an utra short acting and vasodilatory selective .beta..sub.1 -adrenoceptor antagonist, and is devoid of IA. The ultra short-acting and vsodilatory .beta..sub.1 -adrenoceptor blocking activities of vasomolol-a guaiacoxypropanolamine derivative of vanillic acid ethyl ester--were studied. Vasomolol (0.5, 1.0, 3.0 mg/kg, I.v.) produced a dose-dependent bradycardia rsponse, and particularly a hypotensive action with an ultra short-acting property in pentobarbital-anesthetized normotensive rats. Vasomolol's steady-state of .beta.-blockade was attained within 10 min after initiation of an infuson and a rapid recovery from blockade took place after termination of the infusion. In isolated rat aorta, vasomolol (10.sup.-6 M-10.sup.-5 M) inhibit both henylephrine (10.sup.-6 M) and High K.sup.+ (75 mM)--induced smooth muscle contractions, concentration-dependently. This inhibitory effect of vasomolol wa…

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.